drug
avacincaptad pegol sodium
Marketedupdated 5mo agoby Astellas Pharma US Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
AMD
all catalysts(3)
Trials studying avacincaptad pegol sodium
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 11, 2026
37 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jul 11, 2034method-of-use (U-3673)US 11273171
- Jul 11, 2034method-of-use (U-3673)US 11491176
- Jul 11, 2034method-of-use (U-3673)US 12016875
- Feb 14, 2027compositionUS 7579456132d
- Feb 14, 2027compositionUS 9617546132d
- Nov 11, 2026method-of-use (U-3673)US 823677337d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that